11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis, page-6

I would like to re-observe that Dr. Ketelbey, when he was at Pfizer, was instrumental in the testing, development and marketing of what was the leading Alzheimers drug in the world. It helps manage Alzheimers symptoms - delivering mild cognitive benefits. The drug Donepezil (Aricept) is marginally effective over a short duration and has side effects. It has more recently been paired with Memantine for Alzheimers treatment. Aricept is a cholinesterase ( helps retain essential acetylcholine transmitters) inhibitor.

So Dr. Ketelbey has already been medically and financially successful, even with a marginally effective drug, Aricept.
Now, he has the opportunity to take cortisol inhibition, which directly interacts with cholinergic activity and cognitive functionality, and prove its unique biochemistry across perhaps a widespread range of applications for Alzheimers and other cognitive, neurological psychological and metabolic disorders. Further Xanamem testing will likely show that cortisol is a broad causal agent (brain), like "bad" cholesterol and certain fats (liver) was to the massive statin marketplace.

I expect key research, pharmaceutical and grantmaking bodies will formally partner with Actinogen and those ongoing discussions will soon determine the focus, quantity, size, funding and timing of the next studies. My hope is that Dr. Ketelbey and his team will convince large players that the cortisol hypothesis has immense potential and a high probability of successfully benefiting patients and investments. A new mechanism of action, and a new medical paradigm, seem just what the doctor ordered.